新天地 (301277)
NEWLAND PHARMACEUTICAL CO., LTD
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 39207.84
- Circulating A-Shares(W): 39207.84
- Earnings Per Share(RMB): 0.2344
- Net Assets Per Share(RMB): 3.8825
- Operating Revenue(W RMB): 48123.82
- Total Profit(W RMB): 10278.40
- Net Profit Attributable to Parent(W RMB): 9190.07
- Net Profit Growth Rate(%): -35.19
- Weighted Return on Equity(%): 6.0200
- Operating Cash Flow Per Share(RMB): 0.2650
- Undistributed Profit Per Share(RMB): 1.2286
- Capital Reserve Per Share(RMB): 1.3588
2. Main Business
The main business covers:
- Production, R&D and sales of pharmaceutical intermediates
- Production, R&D and sales of active pharmaceutical ingredients (APIs)
- Production, R&D and sales of chemical drug preparations
3. Company Basic Information
- Company Name: Newland Pharmaceutical Co., Ltd.
- Listing Date: 2022-11-16
- Industry: Pharmaceutical Manufacturing
- Address: East side of the south section of Weiwu Road, Changge City, Henan Province
- Website: www.newlandpharma.com
- Company Profile: The company, formerly known as Henan Newland Pharmaceutical Co., Ltd., was restructured into a joint stock company in April 2009. It is primarily engaged in the production, R&D, and sales of pharmaceutical intermediates, APIs, and chemical drug preparations.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | MORGAN STANLEY & CO.INTERNATIONAL PLC. | QFII | 75.96 | 0.75 |
| 2 | UBS AG | QFII | 64.50 | 0.64 |
| 3 | BARCLAYS BANK PLC | QFII | 55.89 | 0.55 |
| 4 | Goldman Sachs International - Proprietary Funds | QFII | 52.10 | 0.52 |
| 5 | Huatai-PineBridge CSI 2000 Index Enhanced Securities Investment Fund A | Fund | 8.63 | 0.09 |
| 6 | China Securities Co., Ltd. Ruixin Flexible Allocation Hybrid Securities Investment Fund A | Fund | 2.17 | 0.02 |
| 7 | Harvest CSI Pharmaceutical Health 100 Strategy ETF | Fund | 1.98 | 0.02 |
| 8 | Southern CSI 2000 ETF | Fund | 1.36 | 0.01 |
| 9 | Penghua China-Hong Kong Emerging Growth Flexible Allocation Hybrid Securities Investment Fund A | Fund | 1.29 | 0.01 |
| 10 | Penghua New Energy Vehicle Theme Hybrid Securities Investment Fund A | Fund | 1.29 | 0.01 |
5. Concept Sectors
- CXO Concept
- Helicobacter Pylori
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- Individual Shareholding
- Inactive Stock
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information